September 20, 2012

Top Biotech Stock Picks for Q4 2012 and Beyond

Interview with UBS Investment Bank Expert Analyst Identifies Equity Winners and Losers

Interview with UBS Investment Bank Expert Analyst Identifies Equity Winners and Losers

67 WALL STREET, New York – September 20, 2012

The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Biotechnology and Pharmaceutical Valuations – Oncology Drug Development – Orphan Drugs – FDA Approval Process – Reimbursement Trends

Companies include: Amgen Inc. (AMGN), Biogen Idec Inc. (BIIB), Celgene Corporation (CELG), Gilead Sciences Inc. (GILD), Alexion Pharmaceuticals, Inc. (ALXN), Merck & Co. Inc. (MRK), Vertex Pharmaceuticals Incorpo (VRTX), Seattle Genetics Inc. (SGEN), Bristol-Myers Squibb Co. (BMY), Idenix Pharmaceuticals Inc. (IDIX), Pharmacyclics Inc. (PCYC), Incyte Corporation (INCY), Pfizer Inc. (PFE) and many others.

Full Article

Tag Cloud

Top Stories